ClinicalTrials.gg
Enrolling by invitationNCT07517510HVA-MPALUpdated Apr 8, 2026

HVA in the Treatment of Mixed-Phenotype Acute Leukemia(MPAL).

A Phase 2 interventional study of HVA in Newly Diagnosed Mixed Phenotype Acute Leukemia (MPAL), sponsored by Guangdong Second Provincial General Hospital. Enrolling by invitation at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-08.

Sponsored by Guangdong Second Provincial General Hospital · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This study aims to evaluate the safety and efficacy of homoharringtonine combined with venetoclax and azacitidine regimen (HVA) in newly diagnosed MPAL patients, providing a basis for the use of the HVA regimen in the treatment of MPAL.

Read the detailed description

Our preliminary studies show that MPAL not only highly expresses BCL-2, but also highly expresses MCL-1, suggesting the need to explore combining MCL-1 inhibitors on the basis of Ven and HMAs. Our preliminary research confirmed that homoharringtonine (HHT) significantly enhances the anti-leukemia effect of Ven/AZA via inhibition of MCL-1. Originally, we designed the HVA regimen by combining HHT with Ven/AZA for the treatment of AML, and achieved better efficacy and safety. Then we exploratively treated 11 MPAL patients with HVA regimen and acquired promising response and safety. In this study, we conduct a multicenter, prospective, single arm trial to evaluate the efficacy and safety of HVA in the treatment of newly diagnosed MPAL.

02

Conditions studied

  • Newly Diagnosed Mixed Phenotype Acute Leukemia (MPAL)

Keywords

  • Mixed Phenotype Acute Leukemia(MPAL)
  • homoharringtonine
  • venetoclax
03

In context

Leukemia, Biphenotypic, Acute

246 studies on the registry are indexed under Leukemia, Biphenotypic, Acute; 53 are open to participants now.

This study's planned enrollment of 40 is below the median of 50 across 185 interventional studies indexed under Leukemia, Biphenotypic, Acute.

Browse Leukemia, Biphenotypic, Acute studies →

Lead sponsor

Guangdong Second Provincial General Hospital is the lead sponsor of 15 studies on the registry; 11 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The patient fully understands this study, voluntarily participates, and signs the form (ICF);
  2. Age ≥18 years;
  3. Newly diagnosed with MPAL according to the World Health Organization (WHO) 2022 classification.
  4. The patient has not started anti-leukemia treatment after the initial diagnosis (except cytoreductive therapy, such as hydroxyurea or cytarabine \<1.0 g/day or );
  5. Expected survival ≥12 weeks;
  6. (ECOG) performance status 0-2;
  7. Normal cardiac function, ≥50%; normal renal function: ≥30 ml/min; normal liver function: \<5 times the normal value, \<3 times the normal value;

Exclusion criteria

Exclusion Criteria:

  1. Patients who have had or currently have other malignant tumors requiring treatment;
  2. Patients with central nervous system (CNS) infiltration;
  3. Other uncontrolled conditions, including but not limited to: (1) uncontrolled or active systemic infections (viral, bacterial, or fungal); (2) chronic virus (HBV) or virus (HCV) requiring treatment; (3) uncontrolled hypertension, etc.;
  4. Patients who cannot take oral medications or have malabsorption syndrome;
  5. Patients with a known history of immediate or delayed reactions to drugs of the same class as the study medication or to ;
  6. Pregnant or breastfeeding women, or patients who refuse to use effective during the study;
  7. Patients with a history of severe neurological or psychiatric disorders who cannot understand or comply with the study protocol;
  8. Patients with severe heart disease, such as myocardial infarction, severe or unstable angina, severe arrhythmias;
  9. Patients known to be infected with (HIV); patients with active hepatitis B or C; subjects who are inactive hepatitis carriers or whose viral hepatitis titers are low after treatment with non-prohibited antiviral drugs are not excluded;
  10. Patients who cannot take oral medications or have malabsorption syndrome;
  11. Patients whom the investigator determines are unsuitable to participate in this study.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    HVA regiment

    HVA regiment for newly diagnosed MPAL

    Drug: HVA

Interventions

  • DrugHVA

    HVA regimen: Venetoclax: 100 mg on day 1, 200 mg on Day 2, 400 mg per day from Day 3 to Day 14; Azacitidine: 75 mg/m2 per day by subcutaneous injection from Day 1 to Day 7; Homoharringtonine : 1mg/m2 per day by intravenous infusion from Day 1 to Day 7. If co-administered with CYP3A inhibitors, the dose of venetoclax was adjusted in accordance with prescribing recommendations. Fms-related receptor tyrosine kinase 3 (FLT3) inhibitors were recommended in patients with FLT3-ITD/TKD mutations. Also tyrosine kinase inhibitors were recommended in patients with BCR/ABL-positive.

06

What researchers measure

Primary outcomes

  1. Composite Complete Remission (CRc)

    The rate of composite complete remission including complete remission (CR) and CR with incomplete blood count recovery (CRi)

    Time frame: At the end of cycle 2 (28 days for a cycle)

Secondary outcomes

  1. Complete remission (CR)

    Camplete remission is defined as BM with\>5% blasts and wthout extramedullary infltration and recovery of peripheral blood cells.

    Time frame: At the end of cycle 2 (28 days for a cycle)

  2. Overall response rate (ORR)

    ORR includes CRc, partial response (PR), and morphologic leukemia-free state(MLFS).

    Time frame: At the end of cycle 2 (28 days for a cycle)

  3. Rate of Measurable residual disease (MRD) negative

    MRD is monitored using flow cytometric analysis with a positive MRD threshold of 0.1%.

    Time frame: At the end of cycle 2 (28 days for a cycle)

  4. Adverse events

    Adverse events including hematologic and nonhematologic toxicities in the treatment of HVA regimen

    Time frame: At the end of cycle 2 (28 days for a cycle)

Other outcomes

  1. Overall survival (OS)

    OS is calculated from enrollment to death or the last follow-up.

    Time frame: 1 year

  2. Relapse-Free Survival (RFS)

    The time from the beginning of the implementation of the mitigation measures to the occurrence of disease progression, any cause of death, or the last follow-up visit

    Time frame: 1 year

  3. Duration of Response (DOR)

    It refers to the period from when the patient achieves CR/CRi until the patient loses CR/CRi.

    Time frame: 1 years

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Apr 2026; primary completion for Dec 2026, 8 months later.

Of 42 phase 2 interventional studies under Leukemia, Biphenotypic, Acute, half reached primary completion within 102 months of starting (the median), counting those still running; a quarter within 47 and three quarters within 153. This study's planned 8 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 1, 2026
First posted
Apr 8, 2026
StartEst.
Apr 1, 2026
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2027
Last update
Apr 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07517510
Lead sponsor
Guangdong Second Provincial General Hospital
Collaborators
Nanfang Hospital, Southern Medical University, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, First Affiliated Hospital of Guangxi Medical University, Guangzhou First People's Hospital, Zhongshan People's Hospital, Guangdong, China, Dongguan People's Hospital, Shenzhen Second People's Hospital
Responsible party
Qing Zhang (Chief Physician, Guangdong Second Provincial General Hospital) — Principal investigator
First posted
Apr 8, 2026
Start date
Apr 1, 2026 (estimated)
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Apr 8, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion